Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GHRS GH Research	$13.08 +0.7%	$13.87	$6.00 ▼ $20.50	$680.53M	0.98	255,797 shs	93,162 shs
GMTX Gemini Therapeutics	$60.35 +1.0%	$56.73	$1.16 ▼ $14.10	$2.61B	-0.12	189,291 shs	349,244 shs
IMVT Immunovant	$15.24 +2.7%	$16.38	$12.72 ▼ $34.47	$2.66B	0.66	1.20 million shs	1.40 million shs
RXRX Recursion Pharmaceuticals	$4.94 +3.3%	$5.46	$3.79 ▼ $12.36	$2.14B	0.93	19.74 million shs	19.86 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GHRS GH Research	0.00%	+2.27%	-9.73%	+17.10%	+17.94%
GMTX Gemini Therapeutics	+1.00%	+0.82%	-0.97%	+27.40%	+20.82%
IMVT Immunovant	0.00%	+0.13%	-16.81%	+5.39%	-53.05%
RXRX Recursion Pharmaceuticals	0.00%	-14.38%	-21.09%	+21.08%	-35.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GHRS GH Research	2.5265 of 5 stars	3.4	3.0	0.0	0.0	2.2	2.5	0.0
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	3.0333 of 5 stars	4.4	2.0	0.0	0.0	2.8	1.7	0.0
RXRX Recursion Pharmaceuticals	2.5407 of 5 stars	3.2	1.0	0.0	0.0	3.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GHRS GH Research	2.88	Moderate Buy	$32.00	144.65% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
IMVT Immunovant	2.83	Moderate Buy	$35.20	130.97% Upside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.00	41.70% Upside

Current Analyst Ratings Breakdown

Latest GHRS, IMVT, GMTX, and RXRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	GHRS GH Research	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2025	IMVT Immunovant	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $37.00
8/12/2025	IMVT Immunovant	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$33.00 ➝ $30.00
8/11/2025	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/28/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$17.00 ➝ $18.00
7/10/2025	IMVT Immunovant	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$18.00
7/8/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
7/3/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$5.00
6/24/2025	GHRS GH Research	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$39.00
6/16/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.00
6/4/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GHRS GH Research	N/A	N/A	N/A	N/A	$3.44 per share	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.16 per share	N/A
RXRX Recursion Pharmaceuticals	$58.84M	36.45	N/A	N/A	$2.61 per share	1.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GHRS GH Research	-$38.96M	-$0.74	0.00	N/A	N/A	N/A	-16.71%	-16.06%	9/2/2025 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
IMVT Immunovant	-$413.84M	-$2.85	0.00	N/A	N/A	N/A	-80.99%	-72.23%	11/6/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$463.66M	-$1.78	0.00	N/A	N/A	-1,004.91%	-76.09%	-54.29%	11/5/2025 (Estimated)

Latest GHRS, IMVT, GMTX, and RXRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2025	Q2 2025	GHRS GH Research	-$0.22	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q1 2026	IMVT Immunovant	-$0.69	-$0.60	+$0.09	-$0.71	N/A	N/A
8/7/2025	Q2 2025	GHRS GH Research	-$0.22	-$0.15	+$0.07	-$0.15	N/A	N/A
8/5/2025	Q2 2025	RXRX Recursion Pharmaceuticals	-$0.35	-$0.41	-$0.06	-$0.41	$15.38 million	$19.10 million
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GHRS GH Research	N/A	29.49	29.49
GMTX Gemini Therapeutics	N/A	71.49	71.49
IMVT Immunovant	N/A	12.32	12.32
RXRX Recursion Pharmaceuticals	0.02	3.58	3.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GHRS GH Research	56.90%
GMTX Gemini Therapeutics	75.42%
IMVT Immunovant	47.08%
RXRX Recursion Pharmaceuticals	89.06%

Insider Ownership

Company	Insider Ownership
GHRS GH Research	N/A
GMTX Gemini Therapeutics	12.90%
IMVT Immunovant	1.80%
RXRX Recursion Pharmaceuticals	8.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GHRS GH Research	10	52.03 million	N/A	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
IMVT Immunovant	120	174.32 million	171.18 million	Optionable
RXRX Recursion Pharmaceuticals	400	434.15 million	397.55 million	Optionable

GHRS, IMVT, GMTX, and RXRX Headlines

Recent News About These Companies

Needham Maintains Buy Rating on Recursion (RXRX)

August 24 at 3:29 AM | msn.com

The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode

August 23 at 4:00 AM | fool.com

Recursion Pharmaceuticals, Inc. $RXRX Stock Position Reduced by Vanguard Group Inc.

August 23 at 3:35 AM | marketbeat.com

Why Recursion Pharmaceuticals Stock Caught a Cold This Week

August 22 at 5:53 PM | fool.com

Recursion Pharmaceuticals (RXRX) Sees Sales And Revenue Growth In Q2 2025

August 22 at 2:13 AM | finance.yahoo.com

Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Sells 36,599 Shares of Stock

August 21 at 9:03 PM | marketbeat.com

Recursion Pharmaceuticals (RXRX) Drops on 3rd Day as Company Execs Dispose of Shares

August 21 at 11:33 AM | insidermonkey.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.3% - Here's Why

August 20, 2025 | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Najat Khan Sells 36,599 Shares

August 20, 2025 | insidertrades.com

EverSource Wealth Advisors LLC Raises Stake in Recursion Pharmaceuticals, Inc. $RXRX

August 20, 2025 | marketbeat.com

LPL Financial LLC Purchases 57,305 Shares of Recursion Pharmaceuticals, Inc. $RXRX

August 20, 2025 | marketbeat.com

Recursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment Data

August 19, 2025 | seekingalpha.com

Liontrust Investment Partners LLP Lowers Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

August 18, 2025 | marketbeat.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by Vestmark Advisory Solutions Inc.

August 18, 2025 | marketbeat.com

Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid

August 17, 2025 | insidermonkey.com

Analysts Set Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) PT at $7.00

August 16, 2025 | americanbankingnews.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Recommendation of "Hold" by Brokerages

August 14, 2025 | marketbeat.com

Recursion Pharmaceuticals: Two Clinical Readouts In H2'25

August 13, 2025 | seekingalpha.com

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by Blair William & Co. IL

August 12, 2025 | marketbeat.com

Recursion Pharmaceuticals’ Earnings Call Highlights Progress and Challenges

August 11, 2025 | theglobeandmail.com

3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term

August 10, 2025 | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GHRS, IMVT, GMTX, and RXRX Company Descriptions

GH Research NASDAQ:GHRS

$13.08 +0.09 (+0.69%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$13.10 +0.02 (+0.15%)

As of 08/22/2025 06:21 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Gemini Therapeutics NASDAQ:GMTX

$60.35 +0.60 (+1.00%)

As of 08/22/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Immunovant NASDAQ:IMVT

$15.24 +0.40 (+2.70%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$15.26 +0.02 (+0.10%)

As of 08/22/2025 06:26 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Recursion Pharmaceuticals NASDAQ:RXRX

$4.94 +0.16 (+3.35%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.01 +0.07 (+1.42%)

As of 08/22/2025 07:59 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time